期刊
ANNALS OF ONCOLOGY
卷 22, 期 6, 页码 1302-1307出版社
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdq585
关键词
ADCC; Fc gamma R; trastuzumab
类别
资金
- Health and Labor Scientific Research Grants [H17-Parmaco-006]
Background: Antibody-dependent-mediated cytotoxicity (ADCC) is one of the modes of action for trastuzumab. Recent data have suggested that fragment C c receptor (Fc gamma R) polymorphisms have an effect on ADCC. This prospective phase II trial aimed to evaluate whether these polymorphisms are associated with clinical efficacies in patients who received trastuzumab. Patients and methods: Patients in a neoadjuvant (N) setting received Adriamycin and cyclophosphamide followed by weekly paclitaxel/trastuzumab. Patients in a metastatic (M) setting received single trastuzumab until progression. In total, 384 distinct single nucleotide polymorphisms of different Fc gamma R, HER2, and fucosyltransferase loci were assessed. Results: Fifteen operable and 35 metastatic HER2-positive breast cancer patients were enrolled in each of the N and M settings, respectively. The Fc gamma R2A-131 H/H genotype was significantly correlated with the pathologically documented response (pathological response) (P = 0.015) and the objective response (P = 0.043). The Fc gamma R3A-158 V/V genotype was not correlated with the pathological response, but exhibited a tendency to be correlated with the objective response. Patients with the Fc gamma R2A-131 H/H genotype had significantly longer progression-free survival in the M setting (P = 0.034). Conclusion: The Fc gamma R2A-131 H/H polymorphism predicted the pathological response to trastuzumab-based neoadjuvant chemotherapy in early-stage breast cancer, and the objective response to trastuzumab in metastatic breast cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据